Strong and Moderate CYP3A Inducers
Concomitant use of pemigatinib with a strong or moderate CYP3A inducer decreases pemigatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may reduce the efficacy of pemigatinib. Avoid concomitant use of strong and moderate CYP3A inducers with pemigatinib.
Strong and Moderate CYP3A Inhibitors
Concomitant use of a strong or moderate CYP3A inhibitor with pemigatinib increases pemigatinib plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the incidence and severity of adverse reactions. Avoid concomitant use of strong and moderate CYP3A inhibitors with pemigatinib. Reduce pemigatinib dosage if concomitant use of strong and moderate CYP3A inhibitors cannot be avoided.
from FDA,2022.08
Pemigatinib is a targeted therapy designed for adult patients with advanced, met···【more】
Release date:2024-08-15Recommended:187
The core mechanism of Pemigatinib, a class of small molecule kinase blockers spe···【more】
Release date:2024-08-15Recommended:144
Pemigatinib is the world's first targeted therapy for cholangiocarcinoma.Wha···【more】
Release date:2024-08-15Recommended:160